Suchergebnisse - "Solomon, Benjamin"

PubPharm (26)

1

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer : OSCILLATE

enthalten in: Nature communications | 2024

von Tan, L. | Brown, C. | Mersiades, A. | +18

2

Metastatic Ablation in Epidermal Growth Factor Receptor Mutated Oligometastatic Non-Small Cell Lung Cancer-Upfront or Outback After Systemic Tyrosine Kinase Inhibitors?

enthalten in: International journal of radiation oncology, biology, physics | 2023

von Siva, S. | Solomon, B.

CommentOn: Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):479-480. - PMID 37270242

3

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers : The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Tan, L. | Tran, B. | Tie, J. | +16

4

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC : the final ASTRIS data

enthalten in: Future oncology (London, England) | 2023

von Cheema, P. | Cho, B. | Freitas, H. | +23

5

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC : Diagnostic and Therapeutic Considerations

enthalten in: Clinical lung cancer | 2022

von Ahn, M. | Mendoza, M. | Pavlakis, N. | +18

6

Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease

enthalten in: JCO precision oncology | 2021

von McLean, L. | Faisal, W. | Parakh, S. | +9

7

EGFR Exon 20 Insertion Mutations : Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical lung cancer | 2021

von Leal, J. | Alexander, M. | Itchins, M. | +9

8

A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2021

von Gan, H. | Burge, M. | Solomon, B. | +13

9

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors : Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

enthalten in: The Journal of molecular diagnostics : JMD | 2018

von Lindeman, N. | Cagle, P. | Aisner, D. | +19

CommentIn: J Mol Diagn. 2018 Mar;20(2):127-128. - PMID 29360582

10

EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma

enthalten in: Medical oncology (Northwood, London, England) | 2017

von Clay, T. | Russell, P. | Do, H. | +7